After adding sodium polystyrene sulfonate (Kayexalate) to infant formula to reduce potassium, can the mixture be refrigerated while it decants?

Refrigeration of Kayexalate-Formula Mixture During Decanting

Yes, the Kayexalate-formula mixture can be refrigerated while it decants, though specific storage guidelines are not explicitly addressed in the available evidence.

Practical Considerations for Storage

The available evidence does not provide explicit guidance on refrigeration during the decanting process. However, several key points inform safe practice:

Decanting Time Requirements

• Contact time of 1 hour is sufficient for effective potassium removal from infant formula when using sodium polystyrene sulfonate (Kayexalate) 1
• Studies demonstrate that 24-hour contact time does not improve potassium removal compared to 1-hour contact time, suggesting extended storage is unnecessary for efficacy 1
• One protocol used a 50-minute decanting period successfully 2

Storage and Preparation Guidelines

• Standard infant formula storage principles should apply: Since the FDA label does not specify storage restrictions for the Kayexalate-formula mixture, and sodium polystyrene sulfonate is not systemically absorbed 3, refrigeration of the mixture should follow normal formula handling practices
• Prepare fresh batches as needed: Given that 1 hour of contact time is adequate 1, there is no therapeutic benefit to prolonged refrigeration of the mixture
• The mixture should be decanted after the appropriate contact time (30-60 minutes) rather than stored for extended periods 4, 2, 5

Recommended Protocol

For optimal safety and efficacy:

• Add Kayexalate to formula at a concentration of 1 gram per mEq of potassium in the formula 6, 4
• Allow the mixture to settle for 30-60 minutes at room temperature or refrigerated 4, 2
• Decant the supernatant after this contact period 7, 2
• Use the treated formula immediately or store according to standard formula storage guidelines (refrigerated, used within 24 hours)

Important Caveats

Electrolyte Alterations

• Kayexalate treatment significantly increases sodium content (up to 324% increase) while reducing potassium by only 25-36% 7, 5
• This creates a disproportionate sodium load that may be problematic for infants with fluid restrictions or hypertension 6
• Calcium and magnesium levels may also be affected by the exchange process 4, 5

Safety Concerns in Neonates

• The FDA label specifically warns that sodium polystyrene sulfonate should not be given by oral route in neonates 3
• Premature and low birth weight infants have increased risk for gastrointestinal adverse effects 8, 3
• Extremely preterm neonates may develop intestinal hemorrhage (hematochezia) from Kayexalate exposure 8

Alternative Considerations

• Preparation with deionized water can reduce potassium content by 30% without the sodium load associated with Kayexalate 2
• Calcium polystyrene sulfonate may be preferable in infants with severe hypertension and hyperkalemia to avoid additional sodium 6